It’s a setback for the company, which has been vying to become the first company to bring a once-weekly basal insulin product ...

Ipsen’s big partnering push to expand its pipeline shows no signs of abating, with the latest deal a $1 billion wager on an ...

Pharma medical writing is an onerous, ongoing activity that could benefit hugely from tech-enabled disruption, and the latest ...

There is change at the top of AbbVie’s R&D organisation, as chief scientific officer Thomas Hudson announces his retirement ...

The Federal Trade Commission in the US is planning to sue the owners of the three largest pharmacy benefits managers (PBMs) ...

The side fund for “sector-specific” partnerships is an interesting element, coming after a wide-ranging, $7 billion alliance ...

ASCO isn’t just a show for top 10 pharmas and Phase 3 readouts; it’s also a conference where smaller biopharmas share ...

When SK Life Science began, it tapped into healthcare providers, patients, and scientists to ensure it was relentlessly focused on medical solutions to help drive success in treating central nervous ...

uniQure is now looking ahead to data from a third cohort in the US phase 1/2 trial of the Huntington’s treatment looking at ...

NHS England has been cleared to allow prescribing of Almirall’s Ebglyss for some people with atopic dermatitis, giving them ...

After a couple of days filled with investor nervousness, Arcutis Biotherapeutics has claimed FDA approval of Zoryve for the ...

When we think of cancer, we think of a fight: a battle between a patient and a mutation to their biology, a transformation – ...